RAC - Charts & Price Action, page-19419

I actually think RC220 could be a less talked about potential commercial catalyst as well...we know RAC are already talking to Big Pharma, given not only the confirmed collaboration with Otsuka, but also Pete being explicit about this in recent investor updates. Pete at the AGM also basically said that BP need to be shown RC220 is the same. If you're BP, and in occasional talks with, or keeping tabs on a target like RAC...if you're aware of the historical data, and market potential, I would think getting in after the RC220 boxes are ticked, or mid trial, would make some sense. At that point, the only thing you're waiting on are results, and we've seen enough good results, and enough "coincidences" that suggest even better results to come. Just my 2 cents...